Increase productivity and align strategy.
Medical affairs teams rely on Sorcero to 10x their productivity, generate evidence, manage insights, and transform their medical strategy with real-time advanced analytics across the therapeutic landscape.
The medical affairs advantage.
Sorcero leverages advanced algorithms and disease-focused ontologies to organize and understand how language is used in Life Sciences. That means you can gain clarity and complete visibility on the efficacy and impact of your scientific engagement on patient outcomes.
Medical Insights Management (MIM)
Accelerate insight generation, analysis, and sentiment validation, while communicating actionable insights to stakeholders with more context and less bias.Read More
Gain a strategic advantage across your disease and therapeutic areas by bringing together advanced analytics for all areas of scientific engagement into one powerful dashboard.Read More
Product Performance Monitoring (PPM)
Stay one step ahead of the changing regulatory environment and keep your products compliant with your personal AI assistant.Read More
WHO WE HELP
Magnify your potential.
Medical affairs is a rapidly growing segment in life sciences and absolutely critical in the successful tracking and adoption of therapeutic products. With a 1,000% increase in productivity and up to a 90% reduction in medical content tracking, transform how medical affairs drives scientific engagement and captures complex insights.
Medical Science Liaisons (MSLs)
Now your MSL team can capture critical insights from your KOLs and enrich them with Sorcero’s powerful AI engine.
Medical Information, Publications, and HEOR
Dramatically increase the productivity of your medical information, publications, and HEOR teams with real-time intelligent literature monitoring and analytics.
Medical Affairs Leadership
Gain a strategic advantage and clarity across your disease and therapeutic areas by bringing together advanced analytics for all areas of scientific engagement in one powerful dashboard.
BY THE NUMBERS
40% of the top 10 global life sciences enterprises have experienced: